# US 2022/0064254 A1 · Anti-hk2 chimeric antigen receptor (car)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064254 A1
- Document ID: US20220064254A1
- Status: Published application
- Kind: A1
- Application number: 16/936,719
- Filed: 2020-07-23
- Published: 2022-03-03
- Earliest claimed: 2019-07-26
- Assignees: Janssen Biotech, Inc.
- Applicants: Janssen Biotech, Inc.
- Inventors: Raymond BRITTINGHAM; Rajkumar GANESAN; Sherry LA PORTE; John T. LEE; Jinquan LUO; Theresa MCDEVITT; Fei SHEN; Sanjaya SINGH; Degang SONG; Sathyadevi VENKATARAMANI; Fang YI; Yonghong ZHAO
- Web page: https://patentgrep.com/patent/US20220064254A1

## CPC

- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4249: {Serine proteases, e.g. kallikrein}
- C07K 14/70517: {CD8}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 16/40: against enzymes
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/812: {Breast}
- A61K 2039/884: {prostate}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/53: Hinge
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a human Kallikrein-2 (hK2), and immunoresponsive cells comprising such CARs, for the treatment of cancer.

## Claims

### Claim 1

A chimeric antigen receptor (CAR) comprising:
(a) an extracellular domain that specifically binds to the human Kallikrein-2 (hK2) antigen,
(b) a transmembrane domain, and
(c) an intracellular signaling domain optionally comprising at least one co-stimulatory domain.

### Claim 2 (depends on 1)

The CAR of claim 1, further comprising
(d) a CD8a-hinge region,
wherein the transmembrane domain comprises a CD8a transmembrane region (CD8a-TM) polypeptide; and
wherein the intracellular signaling domain comprises a co-stimulatory domain comprising a TNF receptor superfamily member 9 (CD137) component and a primary signaling domain comprising a T-cell surface glycoprotein CD3 zeta chain (CD3z) component.

### Claim 3 (depends on 2)

The CAR of claim 2, wherein
the CD8a-hinge region comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 25, 269, 270, 271, or 272;
the transmembrane domain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 26; and/or
the intracellular signaling domain comprises a co-stimulatory domain having an amino acid sequence that is at least 90% identical to SEQ ID NO: 27, and a primary signaling domain having an amino acid sequence that is at least 90% identical to SEQ ID NO: 28.

### Claim 4

A chimeric antigen receptor (CAR), comprising an extracellular antigen-binding domain, a transmembrane domain and an intracellular signaling domain, wherein the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 64, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 66; a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 314, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 315, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 311;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 309, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 310, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 311;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 65, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 66;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 72, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 73, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 66;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 86, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 87, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 88;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 92, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 93, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 94;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 102, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 103, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 104;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 105, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 106, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 104;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 107, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 108, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 109;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 110, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 111, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 109;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 102, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 112, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 113;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 105, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 114, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 113;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 115, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 116, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 117;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 118, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 119, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 117;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 120, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 121, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 122; or
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 123, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 124, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 122,
wherein the extracellular antigen-binding domain binds the hK2 antigen.

### Claim 5

A chimeric antigen receptor (CAR), comprising an extracellular antigen-binding domain, a transmembrane domain and an intracellular signaling domain, wherein the extracellular antigen-binding domain comprises:
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 69, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 71;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 68, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 70, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 71;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 89, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 90, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 91;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 95, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 96, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 71;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 312, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 313, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 91;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 89, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 90, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 91;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 126, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 71;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 128, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 129, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 130;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 125, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 131, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 132;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 133, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 134, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 135;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 136, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 137, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 138; or
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 97, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 127, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 139,
wherein the extracellular antigen-binding domain binds the hK2 antigen.

### Claim 6 (depends on 4)

The CAR according to claim 4, wherein the extracellular antigen-binding domain further comprises:
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 69, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 71;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 68, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 70, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 71;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 89, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 90, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 91;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 95, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 96, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 71;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 89, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 90, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 91;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 126, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 71;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 128, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 129, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 130;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 125, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 131, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 132;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 133, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 134, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 135;
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 136, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 137, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 138; or
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 97, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 127, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 139.

### Claim 7 (depends on 6)

The CAR according to claim 6, wherein the extracellular antigen-binding domain comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 64, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 66, and a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 69, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 71;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 66, and a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 68, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 70, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 71;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 66, and a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 126, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 71;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 66, and a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 69, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 71;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 63, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 65, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 66, and a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 67, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 126, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 71;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 314, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 315, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 311, and a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 312, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 313, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 91;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 102, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 103, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 104, and a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 128, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 129, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 130;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 107, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 108, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 109, and a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 125, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 131, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 132;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 102, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 112, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 113, and a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 133, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 134, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 135;
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 115, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 116, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 117, and a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 136, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 137, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 138; or
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 120, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 121, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 122, and a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 97, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 127, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 138.

### Claim 8 (depends on 6)

The CAR according to claim 6, wherein the extracellular antigen-binding domain comprises: a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 86, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 87, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 88, and a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 89, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 90, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 91.

### Claim 9

A chimeric antigen receptor (CAR), comprising an extracellular antigen-binding domain, a transmembrane domain and an intracellular signaling domain, wherein the extracellular antigen-binding domain comprises:
a light chain variable domain (VL) comprising an amino acid sequence selected from SEQ ID NOS: 1, 2, 3, 74, 75, 147, 148, 149, 150, 151, 152 and 318; and/or
a heavy chain variable domain (VH) comprising an amino acid sequence selected from SEQ ID NOS: 4, 5, 6, 76, 77, 140, 141, 142, 143, 144, 145, 146 and 317;
wherein the extracellular antigen-binding domain binds the human Kallikrein-2 (hK2) antigen.

### Claim 10 (depends on 9)

The CAR of claim 9, wherein the extracellular antigen-binding domain comprises:
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 4;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 2 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 4;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 3 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 6;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 3 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 4;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 2 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 6;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 3 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 4;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 6;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 3 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 5;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 5;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 2 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 5;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 3 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 5;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 74 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 76;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 75 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 77;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 147 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 140;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 75 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 141;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 75 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 140;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 148 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 142;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 149 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 143;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 150 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 144;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 151 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 145;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 152 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 146;
a light chain variable region comprising an amino acid sequence of SEQ ID NO: 318 and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 317.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The CAR of any of claims 1-10, wherein the extracellular antigen-binding domain comprises a single-chain variable fragment (scFv), the scFv comprising a light chain variable region (VL) and a heavy chain variable region (VH).

### Claim 12 (depends on 11)

The CAR of claim 11, wherein the scFv comprises a linker polypeptide between the light chain variable region (VL) and the heavy chain variable region (VH).

### Claim 13 (depends on 12)

The CAR of claim 12, wherein the linker polypeptide comprises an amino acid sequence of SEQ ID NO: 7.

### Claim 14 (depends on 11, 12, 13)

The CAR of any of claims 11-13, wherein the scFv comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 8-23, 169-184 and 340-343.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The CAR of any of claims 1-14, wherein the extracellular antigen-binding domain comprises a signal polypeptide.

### Claim 16 (depends on 15)

The CAR of claim 15, wherein the signal polypeptide comprises an amino acid sequence of SEQ ID NO: 24.

### Claim 17 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The CAR of any of claims 4-16, wherein the intracellular signaling domain comprises a polypeptide component selected from the group consisting of a TNF receptor superfamily member 9 (CD137) component, a T-cell surface glycoprotein CD3 zeta chain (CD3z) component, a cluster of differentiation (CD27) component, a cluster of differentiation superfamily member component, and a combination thereof.

### Claim 18 (depends on 17)

The CAR of claim 17, wherein the CD137 component comprises an amino acid sequence of SEQ ID NO: 27.

### Claim 19 (depends on 17, 18)

The CAR of claim 17 or claim 18, wherein the CD3z component comprises an amino acid sequence of SEQ ID NO: 28.

### Claim 20 (depends on 17, 18, 19)

The CAR of any one of claims 17-19, wherein the intracellular signaling domain comprises an amino acid sequence of SEQ ID NO: 45, or, optionally, the intracellular signaling domain comprises a co-stimulatory domain comprising an amino acid sequence of SEQ ID NO: 27, and a primary signaling domain comprising an amino acid sequence of SEQ ID NO: 28.

### Claim 21 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The CAR of any of claims 4-20, wherein the transmembrane domain comprises a CD8a transmembrane region (CD8a-TM) polypeptide.

### Claim 22 (depends on 21)

The CAR of claim 21, wherein the CD8a-TM polypeptide comprises an amino acid sequence of SEQ ID NO: 26.

### Claim 23 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The CAR of any of claims 4-22, further comprising a hinge region linking the transmembrane domain to the extracellular antigen-binding domain.

### Claim 24 (depends on 23)

The CAR of claim 23, wherein the hinge region is a CD8a-hinge region.

### Claim 25 (depends on 24)

The CAR of claim 24, wherein the CD8a-hinge region comprises an amino acid sequence of SEQ ID NO: 25, 269, 270, 271, or 272.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The CAR of any of claims 1-25, wherein the extracellular antigen-binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 29-44, 78-81, 221-236, and 273-308.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The CAR of any of claims 1-26, wherein the CAR comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 46-61, 82-85 and 205-220.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

An isolated lymphocyte expressing the CAR of any of claims 1-27.

### Claim 29 (depends on 28)

The isolated lymphocyte of claim 28, wherein the lymphocyte is a T lymphocyte.

### Claim 30 (depends on 28)

The isolated lymphocyte of claim 28, wherein the lymphocyte is a natural killer (NK) cell.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

An isolated nucleic acid molecule encoding the CAR of any of claims 1-27.

### Claim 32 (depends on 31)

A vector comprising the nucleic acid molecule of claim 31.

### Claim 33 (depends on 31)

A cell expressing the nucleic acid molecule of claim 31.

### Claim 34 (depends on 28, 29, 30)

A pharmaceutical composition, comprising an effective amount of the lymphocyte of any of claims 28-30.

### Claim 35 (depends on 28, 29, 30)

A pharmaceutical composition, comprising an effective amount of the lymphocyte of any of claims 28-30 and a pharmaceutically acceptable excipient.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 34, 35)

The CAR of any of claims 1-27 or the pharmaceutical composition of claim 34 or 35 for use in therapy.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 34, 35)

The CAR of any of claims 1-27 or the pharmaceutical composition of claim 34 or 35 for use in a method of treating a subject having cancer.

### Claim 38 (depends on 28, 29, 30)

A method of treating a subject having cancer, the method comprising:
administering a therapeutically effective amount of the lymphocyte of any of claims 28-30 to a subject in need thereof, whereby the lymphocyte induces killing of cancer cells in the subject.

### Claim 39 (depends on 37, 38)

The method of claim 38, or the CAR or the pharmaceutical composition for use in a method of claim 37, wherein the cancer is prostate cancer or androgen receptor-expressing breast cancer.

### Claim 40 (depends on 28, 29, 30)

A method of targeted killing of a cancer cell, the method comprising:
contacting the cancer cell with the lymphocyte of any of claims 28-30, whereby the lymphocyte induces killing of the cancer cell.

### Claim 41 (depends on 40)

The method of claim 40, wherein the cancer cell is a prostate cancer cell or androgen receptor-expressing breast cancer cell.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A method of detecting the presence of cancer in a subject, comprising:
contacting a cell sample obtained from the subject with the CAR of any one of claims 1-27, thereby forming a CAR-cell complex, and
detecting the complex, wherein detection of the complex is indicative of the presence of cancer in the subject.
